MiR-92d-3p suppresses the progression of diabetic nephropathy renal fibrosis by inhibiting the C3/HMGB1/TGF-β1 pathway

Running title: miR-92d-3p suppresses diabetic nephropathy renal fibrosis

Yuhua Zhang

College of medicine, Jiangxi University of Technology, Nanchang 330098, Jiangxi, China.

Correspondence to: Yuhua Zhang. College of medicine, Jiangxi University of Technology, NO. 115, Ziyang Avenue, Yaohu University Park, Nanchang 330098, Jiangxi, China. Tel: +86-13970834508, E-mail: yuhuazh4799@163.com
Abstract

The pathogenesis of diabetic nephropathy (DN) has not been fully elucidated. MicroRNAs play an important role in the onset and development of DN renal fibrosis. Thus, this study aimed to investigate the effect of miR-92d-3p on the progression of DN renal fibrosis. We used qRT-PCR to detect the expression levels of miR-92d-3p in the kidneys of patients with DN. Then, after transfecting lentiviruses containing miR-92d-3p into the kidneys of a DN mouse model and HK-2 cell line, we used qRT-PCR to detect the expression levels of miR-92d-3p, C3, HMGB1, TGF-β1, α-SMA, E-cadherin, and Col I. The expression levels of IL-1β, IL-6, and TNF-α in the HK-2 cells were detected through enzyme-linked immunosorbent assay, and Western blotting and immunofluorescence were used in detecting the expression levels of fibronectin, α-SMA, E-cadherin, and vimentin. Results showed that the expression levels of miR-92d-3p in the kidney tissues of patients with DN and DN animal model mice decreased, and C3 stimulated HK-2 cells to produce inflammatory cytokines. The C3/HMGB1/TGF-β1 pathway was activated, and EMT was induced in the HK-2 cells after human recombinant C3 and TGF-β1 protein were added. miR-92d-3p inhibited inflammatory factor production by C3 in the HK-2 cells and the activation of the C3/HMGB1/TGF-β1 pathway and EMT by C3 and TGF-β1. miR-92d-3p suppressed the progression of DN renal fibrosis by inhibiting the activation of the C3/HMGB1/TGF-β1 pathway and EMT.

Keywords: miR-92d-3p; diabetic nephropathy; renal fibrosis; C3; HMGB1; TGF-β1; EMT
1. Introduction

Chronic kidney disease (CKD) is a heterogeneous group of disorders. According to the current US Centers for Disease Control and Prevention (CDC) statistics, 37 million people in the United States are estimated to have CKD. In addition, CKD is more common in people aged 65 years or older (38%) than in people aged 45-64 years (13%) or 18-44 years (7%) (1). The prevalence of type 2 diabetes (T2DM) shows an increasing trend yearly. Statistics from the International Diabetes Federation showed that the number of patients with T2DM may exceed 600 million by 2035. Diabetic nephropathy (DN) is one of the microvascular complications of T2DM and the most common cause of end-stage renal disease (1, 2). Despite the continuous increase in the prevalence of DN globally, its pathogenesis has not been fully elucidated, and highly effective treatments remain inadequate. MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate gene expression and are involved in the onset and development of tubular interstitial sclerosis and end-stage glomerular lesions that occur in various forms in chronic kidney disease (CKD) (3). Therefore, miRNAs are potential therapeutic targets for DN.

The miR-92 family is one of the important miRNA families and involved in the regulation of tumor proliferation, apoptosis, invasion, and metastasis (4-7). R.R. Yang et al. found that miR-92d-3p can regulate the complement pathway by targeting complement component 3 (C3) and thereby control acute immune response to bacterial infection (8). Jun Qiang et al. found that inhibiting miR-92d-3p expression in Nile tilapia head kidney can cause a significant increase in C3 expression and subsequent
increase in the mRNA expression levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interferon-γ (INF-γ) and white blood cell count; thus, inhibited miR-92d-3p expression promotes an inflammatory response in Nile tilapia infected with *Staphylococcus aureus* (9). miR-92d-3p may regulate immune inflammatory response by regulating the activity of C3, but the exact mechanism is unknown.

The deposition of C3, as a member of the complement system in glomeruli, is considered an important cause of various kidney diseases (10). The activation of the glomerulus complement system in diabetic patients can exacerbate glomerular injury, and an injured glomerulus further activates the complement pathway (11). C3 is an acute phase reactant and has an important role in the activation of the complement system. Additionally, C3 may play a role in the development of microvascular diseases (12). In kidney diseases, the deposition of C3 occurs in the glomeruli and glomerular capillaries of animal models. Proteinuria and glomerular damage in mice can be alleviated by inhibiting C3 deposition (13).

HMGB1 can bind to cell surface receptors (such as the receptor of advanced glycosylation end-product [RAGE] and toll-like receptor 4) and may play an important role in promoting TGF-β1 production in DN and renal fibrosis (14). The inhibition of the C3/HMGB1/TGF-β1 signaling pathway can inhibit the progression of renal fibrosis in DN (15). HMGB1 is a DNA-binding protein released by the nucleus into the extracellular fluid through active secretion or passive release, and as a damage-related molecular model molecule (DAMP) (16), can bind to cell surface receptors, such as toll-like receptors (TLR) and RAGE and plays a role in promoting the expression of
inflammatory cytokines, such as TNF-α, IL-1β, and TGF-β1 (17). TGF-β1 is considered a key regulator of renal fibrosis (18). Substantial evidence supports the role of TGF-β in the onset and development of renal fibrosis (19). Meanwhile, the underlying pathology of tubulointerstitial fibrosis is epithelial-to-interstitial transition (EMT) or the transdifferentiation of renal tubular epithelial cells into fibroblasts.

Therefore, this study aims to determine whether miR-92d-3p can target complement C3 to modulate the activity of the C3/HMGB1/TGF-β1 pathway, inhibit immune inflammatory response and EMT associated with DN, and prevent or slow down the progress of DN.

2. Materials and methods

2.1. Patients

A total of 42 patients treated in the Second Affiliated Hospital of Nanchang University from January to December 2018 were selected. Then, 20 of these patients, which had renal trauma and were undergoing nephrectomy, were included in the normal control group, and 22 patients, which had DN and underwent renal biopsy histopathology, were included in the diabetic nephropathy group. All steps were carried out in accordance with the approved topic, and each participant signed written informed consent. DN was diagnosed according to the criteria described in the American Diabetes Association Guidelines published in 2014. The exclusion criteria were as
follows: pregnancy/breastfeeding, type 1 diabetes or other types of diabetes, other types of secondary kidney diseases or those caused by primary kidney diseases, severe hypertension or renal insufficiency caused by high blood pressure, and suffering from urinary tract infection. This study was approved by the medical ethics committee of the College of Medicine of Jiangxi University of Technology and in line with the Declaration of Helsinki.

2.2. Animals and exposure

All animal experiments were performed in the Animal Center College of Medicine of Jiangxi University of Technology. The animal experiment of this study was approved by the animal ethics committee of the College of Medicine of Jiangxi University of Technology. Six-week-old male C57BL/6J mice weighing 24±2 g were purchased from Beijing Huafukang Biotechnology Co., Ltd. and reared in an SPF animal house at 23 °C in a 12 h day/12 h night cycle. Some of the mice were selected as normal controls and fed with a standard diet (8% fat). The other mice received a high-fat diet (HFD) (containing 40% fat) for 8 weeks. A single dose of STZ (30 mg/kg) of 50 mM citrate buffer (pH 4.0) was injected intraperitoneally into the HFD animals daily for 7 days, whereas the normal control group received an equal volume of citrate buffer. One week after the last injection, blood glucose levels were checked. Random blood glucose of ≥16.7 mmol/L was considered diabetes, and 24 h UMA of ≥30 mg was considered DN. Then, the DN mice were randomly divided into the DN model group (n = 10), DN...
model + lentivirus NC (negative control) group (n = 10) and DN model + lentivirus miR-92d-3p group (n = 10). Throughout the experiment, all mice had free access to food and water. The mice were monitored daily, and blood was drawn from the tail vein through standard laboratory methods and used in determining plasma glucose. In addition, the mice received intraperitoneal injection of 0.5% pentobarbital sodium and was sacrificed through carbon dioxide release device.

2.3. Lentiviral transfection

DN mice were transfected with lentivirus overexpressing the miR-92d target gene (synthesized by Shanghai Genechem Technology Co., Ltd.). After abdominal disinfection, 20 mice were anesthetized with 40 mg/kg pentobarbital sodium. The abdominal cavity was opened from the midline of the abdomen until the kidneys were exposed. With a 29-gauge syringe, 150–200 μL of lentiviral vector solution (titer 1×10⁶ cfu/mL) was injected into the kidneys of the mice in the DN model + lentivirus miR-92d-3p group. The kidneys of the mice in the DN model + lentivirus NC group were injected with the same dose of saline. After the incisions were closed, the mice were returned to the cages. On the 28th day, the mice were sacrificed, and the kidneys were removed. The kidney tissues were stored at −80 °C.

2.4. Cell culture and exposure

A renal tubular epithelial cell line (HK-2, American Type Culture Collection,
Rockville, Maryland, USA) was cultured in a DMEM/F12 medium containing 10% FBS (Gibco), placed in an incubator containing 5% CO₂ at 37 °C, digested with 0.05% trypsin, and passaged at a ratio of 1:3 every 5 days.

The cell suspension was inoculated in a 12-well plate at a concentration of 3×10⁵ cells/mL and incubated in a constant temperature incubator at 37 °C for 16–24 h. When the cell fusion rate reached 30%, the medium was changed, and HiTransG P infection enhancer and a medium containing lentiviruses (20 µL/well) were added. The resulting medium was replaced with a conventional medium after cultivation for 16 h, then cultivation was continued. After infection for 72 h, the medium was changed to a serum-free medium, and human recombinant TGF-β1 (10 ng/ml, Peprotech, USA) and human recombinant C3a (20 ng/ml, R&Dsystems, USA) were added according to different groups: ① solvent control, ② C3a, ③ C3a + mimics-NC, and ④ C3a + miR-92d-3p mimics. The expression levels of miR-92d-3p, C3, IL-1β, IL-6, TNF-α, HMGB1, TGF-β1, fibronectin, α-SMA, E-cadherin, and vimentin were determined.

2.5. Western blotting

Total protein were extracted using a radio immunoprecipitation assay lysis buffer (Beyotime, Shanghai, China). The sample was processed through 12% polyacrylamide gel electrophoresis and then transferred onto the PVDF membranes, which were then blocked in 5% nonfat dried milk for 2 h at room temperature. After blocking, primary antibody fibronectin (Abcam, Cambridge, MA, USA), α-SMA (Abcam, Cambridge,
MA, USA), vimentin (Abcam, Cambridge, MA, USA), E-cadherin (Abcam, Cambridge, MA, USA), and GAPDH (Abcam, Cambridge, MA, USA) were added to the membranes. The membranes were incubated at 4 °C overnight and then with HRP-conjugated secondary antibody at 37 °C for 2 h. Finally, a gel imager was used for analysis. GAPDH was used as an internal control. All experiments were performed in triplicate independently.

2.6. Enzyme-linked immunosorbent assay

HK-2 cells were collected, and the levels of IL-1β, IL-6, and TNF-α in the cultured HK-2 cells of each group were detected using an enzyme-linked immunosorbent assay (ELISA) kit (TOPEL02180, Biotopped, Beijing, China). All the steps of the assay were performed according to the manufacturer's instructions.

2.7. qRT-PCR

Total RNA was extracted from the mouse kidney cortex or HK-2 cells, and a first-strand cDNA was constructed using a reverse transcription system kit (Thermo, USA). Exactly 1 μg of RNA was reverse-transcribed into cDNA with RT primers. The primers used were obtained from Genscript Corp (Nanjing, China). The sequences were as follows: miR-92d-3p: TATGGCACTTATCCCGGCC, C3: F: 5'-CAGGCAGGAGGATGTATCGG-3'; R: 5'-TGCCAGCGTCAAGTCTTTTCT-3, HMGB1: F: 5'-CCTCTCAGATTGCACCTCGT-3'; R: 5'-
TATGTCGTCATCCCGCAGTC-3'; TGF-β1: F: 5'-GAGGCGGTGCTCGCTTTGTA-3'; R: 5'-CGTGGCTATTCTTTGTGA-3'; α-SMA: F: 5'-CGGTGGCTATTCTTTGTGA-3'; R: 5'-TGATGCTTTGTAAGGTGGTTC-3', E-cadherin: F: 5'-CCCACCACGTACAAGGGTC-3'; R: 5'-CTGGGGTATTGGGGG CATC-3', Col I: F: 5'-GTACCATGCCCCAACCACA-3'; R: 5'-CACGGATCGGAACCTCGCT-3', GAPDH: F: 5'-GCTGAGTATGTCGTGGAGT-3'; R: 5'-GTTCACACCATC ACAAC-3', U6: RT primer: 5'-CGCTTCAGGAATTTGC TGT-3'; F: 5'-GCTTCGCGCAGCATCTACTAAAAT-3'; R: 5'- CGCTTCACGGAATTTGCGTGCAT-3'. The expression level of miRNA was standardized for U6, and the expression level of the target gene for target U6 was standardized. GAPDH was measured through the Ct (ΔΔCt) method.

2.8. Immunofluorescence

HK-2 cell slides were fixed, penetrated, and closed. Afterward, the slides were mixed with anti-fibronectin (1 μg/mL, Abcam, ab64693, UK), anti-α-SMA (1 μg/mL, Abcam, ab64693, UK), anti-E-cadherin, (1:200, Bioworld Technology, Inc., USA), and anti-vimentin (1:200, Bioworld Technology, Inc., USA) and incubated overnight. Then, the slides were incubated with secondary antibody (1:200, ZB-2306, ZSGB-Bio, Beijing, China) for 1 h according to the manufacturer's instructions and analyzed with a fluorescence microscope.
2.9. Statistical Analysis

SPSS 19.0 was used for statistical analysis. All the values were expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) or LSD test was used in analyzing data. A P value of <0.05 was considered statistically significant. The Pearson correlation coefficients of biological parameters related to miR-92d-3p levels were calculated.

3. Result

3.1 Expression of miR-92d-3p in the kidney tissues of patients with DN was down-regulated.

To investigate the role of miR-92d-3p in DN, we first explored the expression of miR-92d-3p in the kidney tissues of patients with DN through qRT-PCR. miR-92d-3p expression was significantly reduced compared with that in the normal control group (Figure 1A). Then, qRT-PCR was used in detecting the expression levels of C3 (Figure 1B), HMGB1 (Figure 1C), TGF-β1 (Figure 1D), E-cadherin (Figure 1E), α-SMA (Figure 1F), and Col I (Figure 1G). The expression levels of C3, HMGB1, TGF-β1, α-SMA, and Col I in the kidney tissues of patients with DN increased, whereas the expression levels of E-cadherin decreased compared with those in the normal control group.
3.2. Expression of miR-92d-3p was down-regulated in the kidney tissues of DN mice.

Blood glucose levels (Figure 2A) and urine protein levels (Figure 2B) significantly increased compared with those in the control group, indicating that DN mouse model was successfully established. qRT-PCR was then used in detecting the expression levels of miR-92d-3p (Figure 2C), C3 (Figure 2D), HMGB1 (Figure 2E), TGF-β1 (Figure 2F), E-cadherin (Figure 2G), α-SMA (Figure 2H), and Col I (Figure 2I) in the kidney tissues of two groups of mice. The expression levels of C3, HMGB1, TGF-β1, α-SMA, and Col I in the kidney tissues of DN mice increased, whereas the expression levels of miR-92d-3p and E-cadherin decreased compared with those in the normal control group.

3.3. miR-92d-3p suppressed the progression of DN disease by inhibiting the activation of the C3/HMGB1/TGF-β1 pathway.

To study the mechanism of miR-92d-3p, we overexpressed miR-92d-3p in the kidneys of DN mice through lentivirus transfection and detected changes in the blood glucose (Figure 3A) and urine protein levels (Figure 3B) of the mice. qRT-PCR was used in detecting the expression levels of miR-92d-3p (Figure 3C), C3 (Figure 3D), HMGB1 (Figure 3E), TGF-β1 (Figure 3F), E-cadherin (Figure 3G), α-SMA (Figure 3H), and Col I (Figure 3I) in the kidney tissues of the mice in each group. The degree of increase in the expression levels of C3, HMGB1, TGF-β1, α-SMA, and Col I in the kidney tissues of DN model + lentivirus miR-92d-3p group decreased, and the degree
of decrease in the expression levels of miR-92d-3p and E-cadherin decreased compared with those in the DN model group.

3.4. miR-92d-3p inhibited the production of C3-induced inflammatory factors in HK-2 cells.

We transfected miR-92d-3p with lentivirus in cultured renal tubular epithelial HK-2 cells, then recombinant human purified C3 protein was added before the relationship between miR-92d-3p and C3 was observed. qRT-PCR was used in detecting intracellular miR-92d-3p expression in the NC, C3a, C3a + mimics-NC, and C3a + miR-92d-3p mimics groups. The expression levels of miR-92d-3p in the cells of the C3a and C3a + mimics-NC (negative control) groups decreased compared with those in the NC group, whereas the expression levels of miR-92d-3p in the C3a + miR-92d-3p mimics groups were higher than those in the C3a and C3a + mimics-NC groups but decreased compared with the miR-92d-3p expression level in the NC group (Figure 4A). We detected the production of IL-1β (Figure 4B), IL-6 (Figure 4C), and TNF-α (Figure 4D) in the cells in each group with ELISA kits. The results showed that the expression of inflammatory factors in the C3a and C3a + mimics-NC groups increased compared with that in the NC group, indicating that C3a can stimulate the production of inflammatory factors in HK-2 cells. The levels of inflammatory factors in the cells of the C3a + miR-92d-3p mimics group decreased compared with that in the C3a + mimics-NC group, indicating that miR-92d-3p inhibited the production of
inflammatory factors promoted by C3a in the HK-2 cells.

3.5. miR-92d-3p inhibited the activation of C3/HMGB1/TGF-β1 pathway and EMT induced by C3a in HK-2 cells.

qRT-PCR was used in detecting the expression levels of HMGB1 (Figure 5A), TGF-β1 (Figure 5B), and TLR4 (Figure 5C) in each group, and Western blotting were performed for the detection of the expression levels of fibronectin, α-SMA, vimentin, and E-cadherin (Figure 5D). The results showed that the expression levels of HMGB1, TGF-β1, TLR4, fibronectin, α-SMA, and vimentin in the C3a and C3a + mimics-NC groups increased, whereas the expression levels of HMGB1, TGF-β1, TLR4, fibronectin, α-SMA, and vimentin in the C3a + miR-92d-3p mimics group decreased compared with those in the NC group. The expression of E-cadherin showed an opposite result. All the above results suggested that overexpression of miR-92d-3p inhibited the activation of the C3/HMGB1/TGF-β1 pathway and EMT induced by C3a in the HK-2 cells.

3.6. miR-92d-3p inhibited the activation of the C3/HMGB1/TGF-β1 pathway and EMT induced by TGF-β1 in HK-2 cells.

We transfected miR-92d-3p with lentiviruses in cultured renal tubular epithelial HK-2 cells and then added recombinant human purified TGF-β1 protein to observe the relationship between miR-92d-3p and TGF-β1. We used qRT-PCR to detect the expression levels of HMGB1 (Figure 6A) and TLR4 (Figure 6B) in each group and...
used immunofluorescence assays to detect the expression levels of fibronectin, α-SMA, vimentin, and E-cadherin (Figure 6C). The results showed that the expression levels of HMGB1, TLR4, fibronectin, α-SMA, and vimentin in the C3a and C3a + mimics-NC groups increased, and the expression levels of HMGB1, TLR4, fibronectin, α-SMA, and vimentin in the C3a+miR-92d-3p mimics group increased compared with those in the NC group. The expression of E-cadherin showed an opposite result. All the above results suggested that the overexpression of miR-92d-3p inhibited the activation of the C3/HMGB1/TGF-β1 pathway and EMT induced by TGF-β1 in the HK-2 cells.

4. Discussion

T2DM is a serious health problem worldwide(20). DN is one of the most important causes of end-stage kidney disease(21), affecting 15%–25% of patients with T1DM and 30%–40% of patients with T2DM. A cohort study conducted on 95 202 people showed that the use of the Mendelian random allocation method in confirming high concentrations of C3 is associated with increased risk of DN. The determination of plasma C3 may play a central role in risk stratification and screening plan for prediabetic individuals(22). C3 is highly expressed in the kidneys of DN rats and mainly expressed in the renal tubules. It is related to the progression of DN, and the activation of the complement system is a progressive factor of DN(23). Inflammation is a common pathogenic mechanism of CKD(24, 25). In human and animal models, the increased expression of proinflammatory factors is related to the progression of DN(26).
The role of C3a in inflammatory response has been fully demonstrated, and the C3/HMGB1/TGF-β1 pathway activation plays a role in inflammatory response in tilapia head kidney infected by Staphylococcus aureus(9). This process is closely related to the interaction between miR-92d-3p and C3. miR-92d-3p may play an important role in the onset of CKD and the occurrence and development of end-stage glomerular lesions. miR-92 plays an important role in the disease process of organ fibrosis. Wang et al. reported that cardiac-derived exosomes microRNA-92a mediate the activation of myofibroblasts after ischemia in vitro and in vitro(27, 28). Targeting miR-92d-3p is a potential therapeutic target for DN. Thus, studying the relationship of miR-92d-3p with the C3/HMGB1/TGF-β1 pathway and EMT in DN renal fibrosis is necessary.

Podocyte hypertrophy(29), apoptosis(30), and EMT(31) are the main causes of DN. HMGB1 induced by hyperglycemia may cause kidney damage in diabetic rats, and the pathogenic effect of HMGB1 may depend on the activation of RAGE and NF-κB(32). HMGB1 is a damage-related molecular pattern that can be actively or passively released from various cells under different conditions and plays a key role in the pathogenesis of inflammation and angiogenesis-dependent diseases(33). Additionally, HMGB1 is involved in the development of T2DM by inducing autophagy(34), and HMGB1 deletion can inhibit podocyte EMT by inhibiting TGF-β/smad1 signaling(35). Thus, HMGB1, as a proinflammatory cytokine, may play an important role in the progression of DN by inducing increase in downstream TGF-β expression.

In this study, the kidney tissues of patients with DN were first analyzed. The
expression levels of miR-92d-3p decreased compared with miR-92d-3p expression in the control. Then, after the establishment of the DN mouse model, on the DN mouse model with overexpressed miR-92d in the kidneys and models of cell lines with overexpressed miR-92d-3p, mutual verification was conducted in vitro and in vivo. We found that the expression levels of miR-92d-3p in the kidneys of DN mice decreased, and the C3/HMGB1/TGF-β1 pathway was activated. However, the C3/HMGB1/TGF-β1 pathway was inhibited in the kidneys of DN mice with overexpressed miR-92d-3p. Moreover, the expression levels of markers for renal fibrosis, such as vimentin, α-SMA, and Col I decreased. The results of the in vitro cell experiments showed that the supplementation of recombinant purified protein C3a and TGF-β1 can promote the activation of the C3/HMGB1/TGF-β1 pathway and EMT. By contrast, the overexpression of miR-92d-3p can prevent the activation of the pathway and reduce EMT. These results indicated that miR-92d-3p can suppress the progression of DN renal fibrosis by inhibiting the activation of the C3/HMGB1/TGF-β1 pathway.

This study has some shortcomings. The clinical application of miR-92d-3p, as a noncoding RNA, should be further explored. In this study, only lentiviruses were used in overexpressing miR-92d-3p. The knocking down of mir-92D-3P is necessary in verifying the role of miR-92d-3p in fibrosis.

5. Conclusion

During the progression of DN disease, miR-92d-3p interacts with C3 to inhibit the
activation of the C3/HMGB1/TGF-β1 pathway and EMT, thereby preventing the progression of DN renal fibrosis. Our study may provide a theoretical basis for understanding the pathogenesis and treatment of DN.

Data Availability

All the data presented in the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare that they have no conflicts of interest.

Funding information: None.

Author contribution statement: YHZ participated in the design of this study and analyzed and interpreted all data.
References

1. Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. The Journal of Clinical Hypertension. 2021.

2. Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018;71(6):884-95.

3. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015;11(1):23-33.

4. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression. Am J Pathol. 2013;182(5):1876-89.

5. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, et al. The miRNA-17 approximately 92 cluster mediates chemotherapy and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012;26(5):1064-72.

6. Li Y, Li L, Guan Y, Liu X, Meng Q, Guo Q. MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun. 2013;440(4):604-10.

7. Luan X, Zhou X, Naqvi A, Francis M, Foyle D, Nares S, et al. MicroRNAs and immunity in periodontal health and disease. Int J Oral Sci. 2018;10(3):24.

8. Yang R, Zheng T, Cai X, Yu Y, Yu C, Guo L, et al. Genome-wide analyses of amphioxus microRNAs reveal an immune regulation via miR-92d targeting C3. J Immunol. 2013;190(4):1491-500.

9. Qiang J, Tao YF, He J, Li HX, Xu P, Bao JW, et al. Inhibition of miR-92d-3p enhances inflammation responses in genetically improved farmed tilapia (GIFT, Oreochromis niloticus) with Streptococcus iniae infection by modulating complement C3. Fish Shellfish Immunol. 2017;63:367-75.

10. Thurman JM. Complement and the Kidney: An Overview. Adv Chronic Kidney Dis. 2020;27(2):86-94.

11. Fujita T, Ohi H, Komatsu K, Endo M, Ohsawa I, Kanmatsuse K. Complement activation accelerates glomerular injury in diabetic rats. Nephron. 1999;81(2):208-14.

12. Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017;13(5):311-8.

13. Wang H, Vinnikov I, Shahzad K, Bock F, Ranjan S, Wolter J, et al. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. Thromb Haemost. 2012;108(6):1141-53.

14. Cheng M, Liu H, Zhang D, Liu Y, Wang C, Liu F, et al. HMGBl Enhances the AGE-Induced Expression of CTGF and TGF-beta via RAGE-Dependent Signaling in Renal Tubular Epithelial Cells. Am J Nephrol. 2015;41(3):257-66.

15. Wang K, Wei H, Zhan J, Liang X, Zhang C, Liu Y, et al. GSPE alleviates renal fibrosis by inhibiting the activation of C3/ HMGBl/ TGF-beta1 pathway. Chem Biol Interact. 2020;316:108926.

16. Braza F, Brouard S, Chadban S, Goldstein DR. Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nat Rev Nephrol. 2016;12(5):281-90.

17. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al.
mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006;290(3):C917-24.

18. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-38.

19. Hills CE, Squires PE. The role of TGF-beta and epithelial-to-mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 2011;22(3):131-9.

20. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB, Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068-74.

21. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016-27.

22. Rasmussen KL, Nordestgaard BG, Nielsen SF. Complement C3 and Risk of Diabetic Microvascular Disease: A Cohort Study of 95202 Individuals from the General Population. Clin Chem. 2018;64(7):1113-24.

23. Huang Y, Xu J, Wu X, Chen X, Bai X, Zhuang Y, et al. High Expression of Complement Components in the Kidneys of Type 2 Diabetic Rats With Diabetic Nephropathy. Front Endocrinol (Lausanne). 2019;10:459.

24. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97.

25. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-88.

26. Li L, Yin Q, Tang X, Bai L, Zhang J, Gou S, et al. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-beta/smad3 and IKBalpha pathway. PLoS One. 2014;9(11):e113639.

27. Wang X, Morelli MB, Matarase A, Sardu C, Santulli G. Cardiomyocyte-derived exosomal microRNA-92a mediates post-ischemic myofibroblast activation both in vitro and ex vivo. ESC Heart failure. 2020;7(1):285-9.

28. Napoli C, Benincasa G, Donatelli F, Ambrosio G. Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics. American heart journal. 2020.

29. Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121(6):2197-209.

30. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225-33.

31. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol. 2006;17(9):2484-94.

32. Kim J, Sohn E, Kim CS, Jo K, Kim JS. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol. 2011;33(6):524-9.

33. Wu H, Chen Z, Xie J, Kang LN, Wang L, Xu B. High Mobility Group Box-1: A Missing Link between Diabetes and Its Complications. Mediators Inflamm. 2016;2016:3896147.

34. Guo X, Shi Y, Du P, Wang J, Han Y, Sun B, et al. HMGB1/TLR4 promotes apoptosis and reduces
autophagy of hippocampal neurons in diabetes combined with OSA. Life Sci. 2019;239:117020.

35. Jin J, Gong J, Zhao L, Zhang H, He Q, Jiang X. Inhibition of high mobility group box 1 (HMGB1) attenuates podocyte apoptosis and epithelial-mesenchymal transition by regulating autophagy flux. J Diabetes. 2019;11(10):826-36.
Figure legends

Figure 1 Expression levels of miR-92d-3p in the kidneys of patients with DN decreased. qRT-PCR was used in detecting the expression levels of miR-92d (A), C3 (B), HMGB1 (C), TGF-β1 (D), E-cadherin (E), α-SMA (F) and Col I (G). miR-92d-3p was down-regulated in the renal tissues of patients with DN. The C3/HMGB1/TGF-β1 pathway was activated. Data were expressed as mean ± standard. Control group, n = 20; DN group n = 22. Compared with the control group, *P<0.05, **P<0.01, ***P<0.001. Student’s t test.

Figure 2 Expression levels of miR-92d-3p in the kidneys of DN mice decreased. (A) Blood glucose level detection in the control and DN model groups. (B) Urine protein level detection in the control and DN model groups. (C) The expression of mir-92D was detected by qPCR. We used qRT-PCR to detect the expression levels of C3 (D), HMGB1 (E), TGF-β1 (F), E-cadherin (G), α-SMA (H), and Col I (I) in the kidney tissues of the two groups of mice. All values were expressed as mean ± standard, n = 5. Compared with the normal control group, *P<0.05, **P<0.01, ***P<0.001. Student’s t test.

Figure 3 miR-92d-3p reduced the progression of DN renal fibrosis by inhibiting the activation of the C3/HMGB1/TGF-β1 pathway. We overexpressed miR-92d-3p in the kidneys of DN mice through lentivirus transfection and detected changes in blood
glucose (A) and urinary protein (B) in DN mice. We used qRT-PCR to detect the expression levels of miR-92d-3p (C), C3 (D), HMGB1 (E), TGF-β1 (F), E-cadherin (G), α-SMA (H), and Col I (I) in the kidney tissues of the mice in each group. Data were average ± standard (n = 5 per group). *P<0.05, **P<0.01, ***P<0.001. One-way analysis of variance (ANOVA).

**Figure 4** miR-92d-3p inhibited the production of C3-induced inflammatory factors in the HK-2 cells. We used qRT-PCR to detect the expression level of miR-92d-3p in each group (A). We detected the production of IL-1β (B), IL-6 (C), and TNF-α (D) in each group through ELISA. Data were average ± standard. Three biological replicates per group. Compared with the normal control group, *P<0.05, **P<0.01; compared with the C3a+mimics-NC (NC: negative control) group, #P<0.05, ##P<0.01. One-way analysis of variance (ANOVA).

**Figure 5** miR-92d-3p inhibited the activation of the C3/HMGB1/TGF-β1 pathway and EMT induced by C3a in the HK-2 cells. We used qRT-PCR to detect the expression levels of HMGB1 (A), TGF-β1 (B), and TLR4 (C) in each group and performed Western blotting to detect the expression levels of fibronectin, α-SMA, vimentin, and E-cadherin (D). Data were expressed as mean ± standard. Three biological replicates per group. Compared with the normal control group, *P<0.05, **P<0.01; compared with the C3a+mimics-NC group group, #P<0.05, ##P<0.01,
### $P < 0.001$. One-way analysis of variance (ANOVA).

**Figure 6** miR-92d-3p inhibits the activation of the C3/HMGB1/TGF-β1 pathway and EMT induced by TGF-β1 in the HK-2 cells. (A) qRT-PCR to detect the expression levels of HMGB1 in each group. (B) qRT-PCR was used to detect the expression levels of TLR4 in each group. (C) Immunofluorescence experiments was performed for the detection of the expression levels of fibronectin, α-SMA, vimentin, and E-cadherin. Three biological replicates per group. Compared with the normal control group, ***$P < 0.001$; compared with the C3a+mimics-NC group group, $#P < 0.05$, $##P < 0.01$, ###$P < 0.001$. One-way analysis of variance (ANOVA).

**Figure S1** Original Western blots of Figure 5D
